United Therapeutics Corporation $UTHR Position Boosted by AXQ Capital LP

AXQ Capital LP grew its position in United Therapeutics Corporation (NASDAQ:UTHR) by 495.4% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 3,888 shares of the biotechnology company’s stock after purchasing an additional 3,235 shares during the period. AXQ Capital LP’s holdings in United Therapeutics were worth $1,117,000 at the end of the most recent quarter.

A number of other hedge funds have also made changes to their positions in UTHR. Chung Wu Investment Group LLC acquired a new stake in shares of United Therapeutics in the second quarter valued at about $29,000. SVB Wealth LLC acquired a new position in United Therapeutics in the first quarter valued at about $32,000. Geneos Wealth Management Inc. boosted its stake in United Therapeutics by 141.7% in the first quarter. Geneos Wealth Management Inc. now owns 145 shares of the biotechnology company’s stock worth $45,000 after purchasing an additional 85 shares in the last quarter. Brooklyn Investment Group lifted its position in shares of United Therapeutics by 103.2% during the first quarter. Brooklyn Investment Group now owns 193 shares of the biotechnology company’s stock worth $59,000 after purchasing an additional 98 shares in the last quarter. Finally, WPG Advisers LLC bought a new position in United Therapeutics in the first quarter valued at about $60,000. Institutional investors and hedge funds own 94.08% of the company’s stock.

Insider Activity at United Therapeutics

In other United Therapeutics news, COO Michael Benkowitz sold 22,500 shares of United Therapeutics stock in a transaction dated Monday, September 15th. The stock was sold at an average price of $400.56, for a total transaction of $9,012,600.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Insiders sold 519,935 shares of company stock valued at $224,879,377 over the last three months. 10.30% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

Several research firms have recently issued reports on UTHR. Cantor Fitzgerald boosted their target price on United Therapeutics from $405.00 to $525.00 and gave the stock an “overweight” rating in a research report on Wednesday, September 10th. Bank of America raised their target price on shares of United Therapeutics from $314.00 to $463.00 and gave the company a “neutral” rating in a research note on Tuesday, September 2nd. HC Wainwright upped their price objective on shares of United Therapeutics from $500.00 to $525.00 and gave the company a “buy” rating in a report on Thursday, October 30th. Royal Bank Of Canada raised their price target on shares of United Therapeutics from $569.00 to $587.00 and gave the stock an “outperform” rating in a research report on Thursday, October 30th. Finally, Morgan Stanley set a $447.00 price target on shares of United Therapeutics in a report on Wednesday, October 29th. Eight research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. According to MarketBeat.com, United Therapeutics presently has a consensus rating of “Moderate Buy” and an average target price of $505.00.

United Therapeutics Trading Up 0.0%

NASDAQ UTHR opened at $474.82 on Friday. The company has a market cap of $20.44 billion, a P/E ratio of 17.99, a PEG ratio of 4.96 and a beta of 0.77. United Therapeutics Corporation has a 12-month low of $266.98 and a 12-month high of $485.32. The company has a fifty day simple moving average of $439.78 and a 200 day simple moving average of $355.47.

United Therapeutics (NASDAQ:UTHR) last released its quarterly earnings results on Wednesday, October 29th. The biotechnology company reported $7.16 earnings per share for the quarter, beating analysts’ consensus estimates of $6.89 by $0.27. The company had revenue of $799.50 million for the quarter, compared to analyst estimates of $812.87 million. United Therapeutics had a net margin of 40.65% and a return on equity of 18.83%. The firm’s revenue was up 6.8% on a year-over-year basis. During the same period last year, the firm earned $6.39 earnings per share. Sell-side analysts predict that United Therapeutics Corporation will post 24.48 EPS for the current year.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.